MeSH D044882 - glucose metabolism disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AstraZeneca | Dapagliflozin, Saxagliptin | Qtern | 2016-07-15 | $5 M | Y2017 |
Clinical Trials
Historical Success Rate
Phase 1
43%3/7
Phase 2
52%11/21
Phase 3
21%4/19
Approved: 2Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use